Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Anxiety disorders include generalised anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD) and social phobia. Consideration of the chronicity of these disorders reveals that anxiety disorders first occur during early adolescence or young adulthood, and can wax and wane over periods of 5 to 10 years. Thus, in considering treatment, the emphasis must be placed on long term, rather than short term, management. Comorbidity studies reveal that untreated patients with anxiety disorders are at risk of social and psychological consequences, as well as disability resulting from comorbid and secondary disorders.

Comparisons between buspirone and the benzodiazepines in treating patients with generalised anxiety disorder reveal that long term use of benzodiazepines is associated with adverse effects, particularly in elderly patients. Buspirone appears to have an onset of action equivalent to that of the benzodiazepines, to be well tolerated in the long term, to lack problems of habituation and withdrawal, and to be useful in patients with masked comorbid depression.

In patients with panic disorder and social phobia, buspirone has not been clearly shown to be effective in comparison with the reference standards; in those patients with OCD, there are only preliminary indications of efficacy, which merit a more adjunctive role.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1996

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  3. Lader M. Diagnosis and treatment of generalized anxiety disorder. In: Darcourt G, Mendlewicz J, Racagni G, et al., editors. Current therapeutic approaches to panic and other anxiety disorders. Basel: Karger, 1984: 113–20

    Google Scholar 

  4. Schweizer E, Rickeis K, Uhlenhuth EH. Issues in the long-term treatment of anxiety disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation. New York: Raven Press, 1995: 1349–59

    Google Scholar 

  5. Wittchen HU, Essau CA. Epidemiology of anxiety disorders. In: Michels R, editor. Psychiatry, vol.1, 31.1. Philadelphia: Lippencott, 1983: 1–25

    Google Scholar 

  6. Weissman MM, Merikangas KR. The epidemiology of anxiety and panic disorders: an update. J Clin Psychopharmacol 1986; 44 Suppl. 6: 11–7

    Google Scholar 

  7. Hoehn-Saric R, McLeod DR. Generalized anxiety disorder. Psychiatr Clin North Am 1985; 8: 73–88

    PubMed  CAS  Google Scholar 

  8. Wacker HR, Müllejans R, Klein KH, et al. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 1992; 2: 91–100

    Google Scholar 

  9. Wells JE, Bushneil JA, Hornblow AR, et al. Christchurch psychiatric epidemiology study. I: methodology and lifetime prevalence for specific psychiatric disorders. Aust NZ J Psychiatry 1989; 23: 315–26

    CAS  Google Scholar 

  10. Lépine JP, Lellouch J. Classification and epidemiology of anxiety disorders. In: Darcourt G, Mendelwicz J, Racagni G, et al., editors. Current therapeutic approaches to panic and other anxiety disorders. Basel: Karger, 1994: 1–14

    Google Scholar 

  11. Robins L, Regier DA, editors. Psychiatric disorders in America. New York: Free Press, 1991: 23–40

    Google Scholar 

  12. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993; 50: 884–95

    PubMed  CAS  Google Scholar 

  13. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal: a prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–50

    PubMed  CAS  Google Scholar 

  14. Noyes R, Clancy J, Hoenk PR, et al. The prognosis of anxiety disorders. Arch Gen Psychiatry 1980; 37: 173–8

    PubMed  Google Scholar 

  15. Whitaker A, Johnson J, Shaffer D, et al. Uncommon troubles for young people: prevalence estimates of selected psychiatric disorders in a nonreferred adolescent population. Arch Gen Psychiatry 1990; 47: 487–96

    PubMed  CAS  Google Scholar 

  16. Barlow DH, Blanchard EB, Vermilyea JA, et al. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry 1986; 143: 40–4

    PubMed  CAS  Google Scholar 

  17. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993; 150: 600–7

    PubMed  CAS  Google Scholar 

  18. Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology. I: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993; 102: 133–44

    PubMed  CAS  Google Scholar 

  19. Karno G, Golding JM, Sorenson SB, et al. The epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–9

    PubMed  CAS  Google Scholar 

  20. Rapoport JL. The neurobiology of obsessive-compulsive disorder. JAMA 1988; 280: 2888–90

    Google Scholar 

  21. Swedo SE, Rapoport JL, Leonard HL, et al. Obsessive compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989; 46: 335–41

    PubMed  CAS  Google Scholar 

  22. Rapoport JL. The waking nightmare: an overview of obsessivecompulsive disorder. J Clin Psychiatry 1990; 51 (11 Suppl. 1): 25–8

    PubMed  Google Scholar 

  23. Kessler RG, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19

    PubMed  CAS  Google Scholar 

  24. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry 1994; 151: 408–12

    PubMed  CAS  Google Scholar 

  25. Hazen AL, Stein MB. Clinical phenomenology and comorbidity. In: Stein MB, editor. Social phobia: Clinical and research perspectives. Washington, DC: American Psychiatric Press, Inc., 1995: 3–41

    Google Scholar 

  26. Gelernter CS, Stein MB, Tancer ME, et al. An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. J Clin Psychiatry 1992; 53: 2–7

    Google Scholar 

  27. Lelliott P, McNamee G, Marks I. Features of agora-, social, and related phobias and validation of the diagnoses. J Anxiety Disord 1991; 5: 312–22

    Google Scholar 

  28. Perugi G, Simonini E, Savino M, et al. Primary and secondary social phobia: Psychopathologic and familial differentiations. Compr Psychiatry 1990; 31: 245–52

    PubMed  CAS  Google Scholar 

  29. Rapee RM, Sanderson WC, Barlow DH. Social phobia features across the DSM-III-R anxiety disorders. J Psychopathol Behav Assess 1988; 10: 287–99

    Google Scholar 

  30. Barlow DH, DiNardo PA, Vermilyea BB, et al. Comorbidity and depression among the anxiety disorders: issues in classification and diagnosis. J Nerv Ment Dis 1986; 174: 63–7

    PubMed  CAS  Google Scholar 

  31. Breier A, Charney DS, Heninger DR. Agoraphobia with panic attacks: development, diagnostic stability, and course of illness. Arch Gen Psychiatry 1986; 43: 1029–36

    PubMed  CAS  Google Scholar 

  32. Stein MB, Shea CA, Uhde TW. Social phobic symptoms in patients with panic disorder: practical and theoretical implications. Am J Psychiatry 1989; 146: 235–8

    PubMed  CAS  Google Scholar 

  33. DiNardo PA, Barlow DH. Syndrome and symptom co-occurrence in the anxiety disorders. In: Master JD, Cloninger CR, editors. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990: 205–30

    Google Scholar 

  34. Weissman MM, Leaf PJ, Blazer DG, et al. Panic disorder: clinical characteristics, epidemiology, and treatment. Psychopharmacol Bull 1986; 22: 787–91

    PubMed  CAS  Google Scholar 

  35. Boyd JH, Burke JD, Gruenberg E, et al. Exclusion criteria of DSM-III: a study of co-occurrence of hierarchy-free syndromes. Arch Gen Psychiatry 1984; 41: 983–9

    PubMed  CAS  Google Scholar 

  36. Wittchen HU, von Zerssen D, editors. Verläufe behandelter und unbehandelter Depressionen und Angststörungen — Eine klinisch psychiatrische und epidemiologische Verlaufsuntersuching. Heidelberg: Springer, 1988: 232–51

    Google Scholar 

  37. Angst J, Vollrath M, Merikangas KR, et al. Comorbidity of anxiety and depression in the Zurich cohort study of young adults. In: Maser JD, Cloninger CR, editors. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990: 123–53

    Google Scholar 

  38. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and drug abuse. JAMA 1990; 264: 2511–8

    PubMed  CAS  Google Scholar 

  39. Meyer R. Anxiolytics and the alcoholic patient. J Stud Alcohol 1986; 47: 269–73

    PubMed  CAS  Google Scholar 

  40. Wetzler S, Katz MM. Problems with the differentiation of anxiety and depression. J Psychiatr Res 1989; 23: 1–12

    PubMed  CAS  Google Scholar 

  41. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993; 54 Suppl. 1: 20–3

    PubMed  Google Scholar 

  42. Breier A, Charney DS, Heninger GR. Major depression in patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41: 129–35

    Google Scholar 

  43. Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: development, diagnostic stability, and course of illness. Arch Gen Psychiatry 1986; 43: 1029–36

    PubMed  CAS  Google Scholar 

  44. Stein MB, Uhde TW. Panic disorder in major depression: a tale of two syndromes. Psychiatr Clin North Am 1988; 11: 441–61

    PubMed  CAS  Google Scholar 

  45. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia. I: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988; 45: 437–43

    PubMed  CAS  Google Scholar 

  46. Karno M, Golding JM, Sorenson SB, et al. Epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–9

    PubMed  CAS  Google Scholar 

  47. Rasmussen SA, Eison JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1992: 53 Suppl. 4: 4–10

    PubMed  Google Scholar 

  48. Rasmussen SA, Eison JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in obsessive-compulsive disorder. Psychopharmacol Bull 1988; 24: 466–70

    PubMed  CAS  Google Scholar 

  49. Schneier FR, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993; 13: 251–6

    PubMed  CAS  Google Scholar 

  50. Van Ameringen M, Mancini C, Styan G, et al. Phármacotherapy of social phobia with other psychiatric illness. J Affect Disord 1991; 28: 305–8

    Google Scholar 

  51. Zozecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry 1995; 56 Suppl. 2: 10–3

    Google Scholar 

  52. Weissman MM, Klerman G, Markowitz J, et al. Suicide ideation and suicide attempts in panic disorder and attacks. N Engl J Med 1989; 321: 1209–13

    PubMed  CAS  Google Scholar 

  53. Johnson J, Weissman MM, Klerman GL. Panic disorder, comorbidity, and suicide attempts. Arch Gen Psychiatry 1990; 47: 805–8

    PubMed  CAS  Google Scholar 

  54. Lépine JP, Chignon JM, Téhérani M. Suicide attempts in patients with panic disorder. Arch Gen Psychiatry 1993; 50: 144–9

    PubMed  Google Scholar 

  55. Noyes R. Suicide and panic disorder: a review. J Affect Disord 1991; 22: 1–11

    PubMed  Google Scholar 

  56. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder: a comparison with primary unipolar depression. Arch Gen Psychiatry 1982; 39: 701–3

    PubMed  CAS  Google Scholar 

  57. Coryell W, Noyes R, House JD. Mortality among outpatients with anxiety disorders. Am J Psychiatry 1986; 143: 508–10

    PubMed  CAS  Google Scholar 

  58. Allgulander C, Lavori PN. Excess mortality among 3302 patients with pure anxiety neurosis. Arch Gen Psychiatry 1991; 48: 599–605

    PubMed  CAS  Google Scholar 

  59. Friedman S, Jones JC, Chernan L, et al. Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics. Am J Psychiatry 1992; 149: 680–5

    PubMed  CAS  Google Scholar 

  60. Angst J, Degonda M, Ernst C. The Zurich study. XV: Suicide attempts in a cohort from age 20 to 30. Eur Arch Psychiatry Clin Neurosci 1992; 242: 135–41

    PubMed  CAS  Google Scholar 

  61. Rahe RH. Anxiety and physical illness. J Clin Psychiatr 1988; 49 Suppl. 10: 26–29

    Google Scholar 

  62. Rozinski A, Bacrey CN, Krantz DS. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med 1988; 318: 1008–12

    Google Scholar 

  63. Outlier LW. Mixed bipolar disorder responsive to lithium and clonazepam. J Clin Psychiatry 1986; 47: 49–50

    Google Scholar 

  64. Alexander PE, Alexander DD. Alprazolam treatment for panic disorders. J Clin Psychiatry 1986; 47: 301–4

    PubMed  CAS  Google Scholar 

  65. APA Task Force (American Psychiatric Association Task Force). Benzodiazepine dependence, toxicity and abuse. Washington, DC: American Psychiatric Press, Inc., 1990

    Google Scholar 

  66. Arana GW, Ornsteen ML, Kanter F, et al. The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 1986; 22: 77–87

    PubMed  CAS  Google Scholar 

  67. Ashton H. Benzodiazepine withdrawal: an unfinished story. BMJ 1984; 88: 1135–40

    Google Scholar 

  68. Avorn J, Dreyer P, Connelly K, et al. Use of psychoactive medications and the quality of care in rest homes: findings and policy implications of a statewide study. N Engl J Med 1989; 320: 227–33

    PubMed  CAS  Google Scholar 

  69. Saltzman C, Watsky E. Rational prescribing of benzodiazepines. In: Hallstrom C, editor. Benzodiazepine dependence. Oxford: Oxford University Press, 1993: 13–33

    Google Scholar 

  70. Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines. Part I. N Engl J Med 1983; 309: 354–8

    PubMed  CAS  Google Scholar 

  71. Trimble MR. Benzodiazepines divided. New York: John Wiley & Sons, 1983: 121–35

    Google Scholar 

  72. Tyrer P. The place of tranquillizers in the management of stress. J Psychosom Res 1983; 27: 385–90

    PubMed  CAS  Google Scholar 

  73. Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 1987; 39: 251–9

    PubMed  CAS  Google Scholar 

  74. Rickels K. Benzodiazepines in the treatment of anxiety: North American experiences. In: Costa E, editor. The benzodiazepines: from molecular biology to clinical practice. New York: Raven Press, 1983: 295–310

    Google Scholar 

  75. Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines. JAMA 1988; 260: 3476–80

    PubMed  CAS  Google Scholar 

  76. Rickels K, Case GW, Winokur A, et al. Long-term benzodiazepine therapy: benefits and risks. Psychopharmacol Bull 1984; 20: 608–15

    PubMed  CAS  Google Scholar 

  77. Kleber RJ. A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology. J Clin Psychiatry 1979; 40: 165–70

    PubMed  CAS  Google Scholar 

  78. Kahn RJ, McNair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depression and anxiety disorders. Arch Gen Psychiatry 1986; 43: 79–85

    PubMed  CAS  Google Scholar 

  79. Pecknold JC, McClure DJ, Elie R, et al. Trimipramine and araitriptyline: comparison in anxiety depression. Curr Ther Res 1979; 26: 497–502

    Google Scholar 

  80. Assalian P, Rosengarten MD, Phillips R. A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of doxepin in depressed hospitalized patients. J Clin Psychiatry 1985; 46: 90–4

    PubMed  CAS  Google Scholar 

  81. Pecknold JC, Familamiri P, McClure DJ, et al. Trimipramine and maprotiline: antidepressant, anxiolytic and cardiotoxic comparison. J Clin Psychiatry 1985; 46: 166–71

    PubMed  CAS  Google Scholar 

  82. Gorman JM, Papp LA. Chronic anxiety: deciding the length of treatment. J Clin Psychiatry 1990; 51 Suppl. 1: 11–5

    PubMed  Google Scholar 

  83. Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48 Suppl.: 3–6

    PubMed  Google Scholar 

  84. Feighner JP, Merideth CH, Henrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103–7

    PubMed  CAS  Google Scholar 

  85. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81–6

    PubMed  CAS  Google Scholar 

  86. Wheatley D. Buspirone: multicenter efficacy study. J Clin Psychiatry 1982; 43: 92–4

    PubMed  CAS  Google Scholar 

  87. Pecknold JC, Matas M, Howarth BG, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 1989; 34: 706–71

    Google Scholar 

  88. Böhm C, Placchi M, Stallone F, et al. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 1990; 10: 38S–42S

    PubMed  Google Scholar 

  89. Cohn JB, Bowden CL, Fisher JG, et al. Double-blind comparison of buspirone and clorazepate in anxious patients. Am J Medicine 1986; 80: 10–6

    CAS  Google Scholar 

  90. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry 1986; 47: 409–12

    PubMed  CAS  Google Scholar 

  91. Petracca A, Nisita C, McNair D, et al. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 1990; 51 Suppl.: 31–9

    PubMed  Google Scholar 

  92. Strand M, Hetta J, Rosen A, et al. A double-blind controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51 Suppl. 9: 40–5

    PubMed  Google Scholar 

  93. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979; 136: 1184–7

    PubMed  CAS  Google Scholar 

  94. Olajide D, Lader M. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 1987; 7: 148–55

    PubMed  CAS  Google Scholar 

  95. Hamilton M. Diagnosis and ratings of anxiety. Br J Psychiatry 1969; 3: 76–9

    Google Scholar 

  96. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks’ treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529–34

    PubMed  CAS  Google Scholar 

  97. Hollister LE, Motzenbecker FP, Degan RO. Withdrawal reactions from chlordiazepoxide (Librium). Psychopharmacologia 1961; 2: 63–8

    PubMed  CAS  Google Scholar 

  98. Covi L, Lipman RS, Pattison JH, et al. Length of treatment with anxiolytic sedatives and response to their sudden withdrawal. Acta Psychiatr Scand 1973; 49: 51–64

    PubMed  CAS  Google Scholar 

  99. Preskorn E, Denner J. Benzodiazepines and withdrawal psychosis: report of three cases. JAMA 1977; 237: 36–8

    PubMed  CAS  Google Scholar 

  100. Pecknold JC, McClure DJ, Fleuri D, et al. Benzodiazepine withdrawal effects. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 517–22

    PubMed  CAS  Google Scholar 

  101. Lapierre YD, Tremblay A, Gagnon A, et al. A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis. J Clin Psychiatry 1982; 43: 372–4

    PubMed  CAS  Google Scholar 

  102. Fontaine R, Annable L, Chouinard G. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentration. J Clin Psychopharmacol 1983; 3: 80–7

    PubMed  CAS  Google Scholar 

  103. Swinson RP, Pecknold JC, Kirby ME. Benzodiazepine dependence. J Affect Disord 1987; 13: 109–18

    PubMed  CAS  Google Scholar 

  104. Marks J. The benzodiazepines - use, overuse, misuse, abuse. Lancaster: MTP Press, Ltd., 1978

    Google Scholar 

  105. Browne JL, Hauge KJ. A review of alprazolam withdrawal. Drug Intell Clin Pharm 1986; 20: 837–40

    PubMed  CAS  Google Scholar 

  106. Lader M. Benzodiazepines - the opium of the masses? Neuroscience 1978; 3: 159–65

    PubMed  CAS  Google Scholar 

  107. Tyrer P. The benzodiazepine bonanza. Lancet 1974; II: 709–10

    Google Scholar 

  108. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43: 69–75

    PubMed  CAS  Google Scholar 

  109. Lader M. Can buspirone induce rebound, dependence or abuse? Br J Psychiatry 1991; 159 Suppl. 12: 45–51

    Google Scholar 

  110. Pecknold JC, Familamiri P, Chang H, et al. Buspirone: anxiolytic? Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 639–42

    PubMed  CAS  Google Scholar 

  111. Fontaine R, Chouinard G, Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984; 141: 848–52

    PubMed  CAS  Google Scholar 

  112. Moring J, Alarotu P, Haukijarvi A, et al. Buspirone vs diazepam in treatment of anxiety in general practice. In: Psychiatry today: accomplishments and promises. New York: Plenum, 1989: 120–7

    Google Scholar 

  113. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529–34

    PubMed  CAS  Google Scholar 

  114. Schweizer E, Rickels KR. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986; 143: 1590–2.

    PubMed  CAS  Google Scholar 

  115. Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 1987; 7: 11–5

    PubMed  CAS  Google Scholar 

  116. Udelman D, Udelman DL. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry 1990; 51 Suppl. 9: 46–50

    PubMed  Google Scholar 

  117. Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984; 27: 132–47

    PubMed  CAS  Google Scholar 

  118. Bond A, Lader M, Shotriya RR. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol 1983; 24: 463–7

    PubMed  CAS  Google Scholar 

  119. Brown CR. The use of benzodiazepines in prison populations. J Clin Psychiatry 1978; 39: 219–22

    PubMed  CAS  Google Scholar 

  120. Johnson CL, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology 1982; 76: 101–3

    PubMed  CAS  Google Scholar 

  121. Wittenborn JR, Flaherty CF, McGough WE, et al. Psychomotor changes during initial day of benzodiazepine medication. Br J Clin Pharmacol 1979; 7: 69S–76S

    PubMed  Google Scholar 

  122. Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 1986; 23: 179–213

    PubMed  CAS  Google Scholar 

  123. Peturrson H, Gudjonsson GH, Lader MH. Psychometric performance during withdrawal from long-term benzodiazepine treatment. Psychopharmacology 1983; 81: 345–9

    Google Scholar 

  124. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365–74

    PubMed  CAS  Google Scholar 

  125. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986; 88: 426–33

    PubMed  CAS  Google Scholar 

  126. Bond A. The risks of taking benzodiazepines. In: Hallstrom C, editor. Benzodiazepine dependence. Oxford: Oxford University Press, 1993: 34–45

    Google Scholar 

  127. Oster G, Russell MW, Huse DM, et al. Accident - and injuryrelated health-care utilization among benzodiazepine users and nonusers. J Clin Psychiatry 1987; 48 Suppl.: 17–21

    PubMed  Google Scholar 

  128. Sellers EM, Busto U. Benzodiazepines and ethanol: assessment of the effects and consequences of psychotropic drug interactions. J Clin Psychopharmacol 1982; 2: 24–62

    Google Scholar 

  129. Skegg DCG, Richards SM, Doll R. Minor tranquillizers and road accidents. BMJ 1979: 1: 917–9

    PubMed  CAS  Google Scholar 

  130. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990; 51: 1 Suppl.: 3–10

    Google Scholar 

  131. Kastenholz KV, Crimson ML. Buspirone, a novel nonbenzodiazepine anxiolytic. Clin Pharm 1984; 3: 600–7

    PubMed  CAS  Google Scholar 

  132. Ayd FJ. Buspirone update: comparison with the benzodiazepines. Int Drug Ther Newslett 1985; 20: 37–43

    Google Scholar 

  133. Zisook S, de Vaul RA. Adverse behavioral effects of benzodiazepines. J Fam Pract 1979; 5: 963–6

    Google Scholar 

  134. Pyke RE, Kraus M. Alprazolam in the treatment of panic attack patients with and without major depression. J Clin Psychiatry 1988; 49: 66–8

    PubMed  CAS  Google Scholar 

  135. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306(18): 1081–8

    PubMed  CAS  Google Scholar 

  136. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169–73

    PubMed  CAS  Google Scholar 

  137. Ancill RJ, Embury GD, MacEwan GW, et al. Lorazepam in the elderly — a retrospective study of the side effects in 20 patients. J Clin Psychopharmacol 1987; 2: 126–7

    Google Scholar 

  138. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9

    PubMed  CAS  Google Scholar 

  139. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short term elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7

    PubMed  CAS  Google Scholar 

  140. Schnabel Jr T. Evaluation of the safety and side effects of antianxiety agents. Am J Med 1987; 82 Suppl. 5A: 7–13

    PubMed  Google Scholar 

  141. Smiley A, Moscowitz H. Effects of long term administration of buspirone and diazepam on driver steering control. Am J Med 1988; 80 Suppl. 3B: 22–9

    Google Scholar 

  142. Moscowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43: 45–55

    Google Scholar 

  143. Matilla M, Seppala T, Maulla MJ. Combined effects of buspirone and diazepam on objective and subjective tests of performance in healthy volunteers. Clin Pharmacol Ther 1986; 40: 620–6

    Google Scholar 

  144. Boulenger JP, Squillace K, Simon P, et al. Buspirone and diazepam: comparison of subjective, psychomotor and biological effects. Neuropsychobiology 1989; 22: 83–9

    PubMed  CAS  Google Scholar 

  145. Robinson DS, Rickels K, Feighner J. Clinical effects of the 5-HT 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 Suppl.: 67S–76S

    PubMed  CAS  Google Scholar 

  146. Schweizer EE, Amsterdam J, Rickels K, et al. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986; 22: 183–5

    PubMed  CAS  Google Scholar 

  147. Meyer RE. Anxiolytics and the alcoholic patient. J Stud Alcohol 1987; 47: 269–73

    Google Scholar 

  148. Kranzler HR. Preliminary studies on the effects of buspirone on craving in alcoholics [abstract]. Am Coll Neuropsychopharmacol 1987 Dec; Conference; 1987 Dec 5–11; San Juan, Puerto Rico

  149. Shrotriya RC, Caston GP. Buspirone: use in treating alcohol abuse. US Pat. No. 4, 777, 173, 1988

  150. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22 Suppl. 1: 49–59

    PubMed  Google Scholar 

  151. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcohol population with selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12: 19–26

    PubMed  CAS  Google Scholar 

  152. Olivera AA, Sarvis S, Heard C. Anxiety disorders coexisting with substance dependence: treatment with buspirone. Curr Ther Res 1990; 47: 52–61

    Google Scholar 

  153. Malcolm R, Anton RF, Randall CL, et al. A placebo controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16: 1007–13

    PubMed  CAS  Google Scholar 

  154. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988; 45: 413–22

    PubMed  CAS  Google Scholar 

  155. Cross National Collaborative Panic Study, second phase investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992; 160: 191–202

    Google Scholar 

  156. Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective double-blind, placebocontrolled trial. J Clin Psychiatry 1987; Suppl. 48: 16–21

    PubMed  Google Scholar 

  157. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III: Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–36

    PubMed  CAS  Google Scholar 

  158. Pecknold JC, Munjack D, Alexander P. A double-blind, placebocontrolled multicenter study using alprazolam and alprazolam XR in the treatment of panic disorder. J Clin Psychiatry 1994; 14(5): 314–21

    CAS  Google Scholar 

  159. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964; 53: 397–408

    Google Scholar 

  160. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962; 119: 432–8

    PubMed  CAS  Google Scholar 

  161. Ballenger JC, Peterson GA, Laraia M, et al. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In: Ballenger JC, editor. Biology of agoraphobia. Washington, DC: American Psychiatric Association Press, 1984: 27–63

    Google Scholar 

  162. Ballenger JC, Sheehan DV, Jacobson G. Antidepressant treatment of severe phobic anxiety. Abstracts of the Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association; 1977 May 7-14; Toronto

    Google Scholar 

  163. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affect Disord 1987; 13: 153–6

    PubMed  CAS  Google Scholar 

  164. Mavissakalian M, Perel J, Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J Clin Psychopharmacol 1984; 4: 36–40

    PubMed  CAS  Google Scholar 

  165. Sheehan DV, Ballenger JC, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51–9

    PubMed  CAS  Google Scholar 

  166. Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63–72

    PubMed  CAS  Google Scholar 

  167. Zitrin CM, Klein DF, Woerner MG, et al. Treatment of phobias. I: Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125–38

    PubMed  CAS  Google Scholar 

  168. Amin MM, Ban TA, Pecknold JC, et al. Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders. J Int Med Res 1977; 5 Suppl. 5: 33–7

    PubMed  Google Scholar 

  169. Escobar JI, Landbloom RP. Treatment of phobic neurosis with clomipramine: a controlled clinical trial. Curr Ther Res 1976; 20: 680–5

    PubMed  CAS  Google Scholar 

  170. Karabanow O. Double-blind controlled study in phobias and obsessions. J Int Med Res 1977; 5 Suppl. 5: 42–8

    PubMed  Google Scholar 

  171. Johnston DG, Troyer IE, Whitstett SE Clomipramine in the treatment of agoraphobic women. Arch Gen Psychiatry 1988; 40: 605–12

    Google Scholar 

  172. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder. J Clin Psychopharmacol 1992; 12: 251–61

    PubMed  CAS  Google Scholar 

  173. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1993; 167: 374–9

    Google Scholar 

  174. Black DW, Wesener R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 44–50

    PubMed  CAS  Google Scholar 

  175. Höehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321–6

    PubMed  Google Scholar 

  176. Westenberg HGM, den Boer JA. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59–74

    PubMed  Google Scholar 

  177. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double-blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Beri) 1990; 102: 85–94

    Google Scholar 

  178. Evans L, Kenardy J, Schneider P, et al. Effects of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr Scand 1986; 73: 49–53

    PubMed  CAS  Google Scholar 

  179. Boyer W. Serotonin uptake inhibitors are superior to imipramine in alleviating panic attacks. In: Darcourt G, Mendlewicz J, Racagni G, et al., editors. Current therapeutic approaches to panic and other anxiety disorders. New York: Karger, 1994: 55–60

    Google Scholar 

  180. Kelley D, Guirguis W, Frommer E, et al. Treatment of phobic states with antidepressants. Br J Psychiatry 1970; 116: 387–98

    Google Scholar 

  181. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone. J Clin Psychiatry 1986; 47: 580–6

    PubMed  CAS  Google Scholar 

  182. Cox DJ, Ballenger JC, Laraia M, et al. Different rates of symptomatic improvement in pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry 1988; 19(2): 119–26

    PubMed  CAS  Google Scholar 

  183. Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7(5): 329–32

    PubMed  CAS  Google Scholar 

  184. Telch MJ, Agras WS, Taylor CB, et al. Combined pharmacological and behavioral treatment for agoraphobia. Behav Res Ther 1985; 23: 325–35

    PubMed  CAS  Google Scholar 

  185. Liebowitz MR. Imipramine in the treatment of panic disorder and its complications. Psychiatr Clin N Am 1985; 8: 37–47

    CAS  Google Scholar 

  186. Pohl R, Balon R, Yeragani VK. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22 Suppl.: 60–9

    PubMed  Google Scholar 

  187. Gastfriend DR, Rosenbaum JF Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 1989; 146(7): 914–6

    PubMed  CAS  Google Scholar 

  188. Robinson DS, Shrotriya RC, Alms DR, et al. Treatment of panic disorder: use of nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull 1989; 25: 21–6

    PubMed  CAS  Google Scholar 

  189. Sheehan DV, Raj AB, Sheehan H, et al. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 1988; 29: 815–7

    PubMed  CAS  Google Scholar 

  190. Sheehan DV, Raj AB, Sheehan KH, et al. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10: 3–11

    PubMed  CAS  Google Scholar 

  191. Fernandez-Cardoba E, Lopez-Ibor Jr JJ, Alino J. La monoclorimipramina en enfermos psiquitricos resistentes a otros tratiamentos. Acta Luso-Esp Neurol Psiquiatr Ciene Afines 1967; 26: 119–47

    Google Scholar 

  192. Montgomery SA. Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharmacol Med 1980; 1: 189–92

    Google Scholar 

  193. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder. I: A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281–5

    PubMed  CAS  Google Scholar 

  194. Flament MF, Rapoport J, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985; 42: 83–97

    Google Scholar 

  195. Rapoport J, Elkins R, Mikkelson E. Clinical controlled trial of clorimipramine in adolescents with obsessive-compulsive disorder. Psychopharmacol Bull 1980; 16: 61–5

    PubMed  CAS  Google Scholar 

  196. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730–8

    Google Scholar 

  197. Rasmussen SA. A multicenter controlled trial of fluvoxamine in the treatment of OCD. Presented at the 145th Annual Meeting of the American Psychiatric Association; 1992 May 5; Washington DC

    Google Scholar 

  198. Greist JH. A double-blind comparison of three doses of sertraline and placebo in the treatment of obsessive compulsive disorders. Presented at the XVIIIth Collegium Internationale Neuro-Psychopharmacologicum Congress; 1992 June 11–14; Nice

    Google Scholar 

  199. Wheadon D. A double-blind comparison of three doses of fluvoxamine and placebo in the treatment of obsessive-compulsive disorder. Presented at the World Congress for Biologic Psychiatry; 1991 June 15–23; Florence

    Google Scholar 

  200. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577–85

    PubMed  CAS  Google Scholar 

  201. Leonard H, Swedo SE, Rapoport JL, et al. Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry 1989; 46: 1088–92

    PubMed  CAS  Google Scholar 

  202. Montgomery SA, Osterheider M, Sarteschi P, et al. A doubleblind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993; 3(2): 143–52

    PubMed  CAS  Google Scholar 

  203. Pease TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 1543–8

    Google Scholar 

  204. Chouinard G. Sertraline in the treatment of obsessive-compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992; 7 Suppl.: 37–41

    PubMed  Google Scholar 

  205. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147: 1209–15

    PubMed  CAS  Google Scholar 

  206. Jenike MA, Baer L. An open trial of buspirone in obsessivecompulsive disorder. Am J Psychiatry 1988; 145: 1285–6

    PubMed  CAS  Google Scholar 

  207. Jenike MA, Bear L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991; 52: 13–4

    PubMed  CAS  Google Scholar 

  208. Markowitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 798–800

    Google Scholar 

  209. Grady TA, Pigott TA, L’Heureux F, et al. A double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 819–21

    PubMed  CAS  Google Scholar 

  210. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refrac-tory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 647–9

    PubMed  CAS  Google Scholar 

  211. Pigott TA, L’Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder. J Clin Psychopharmacol 1992; 12: 11–8

    PubMed  CAS  Google Scholar 

  212. Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127–9

    PubMed  CAS  Google Scholar 

  213. Rasmussen SA, Eison JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 1993; 54(6): 4–9

    PubMed  Google Scholar 

  214. Dolberg OT, Sasson Y, Kindler S, et al. Neurobiology and treatment of obsessive-compulsive disorder. In: Darcourt G, Mendelwicz J, Racagni G, et al., editors. Current therapeutic approaches to panic and other anxiety disorders. New York: Karger, 1993: 151–8

    Google Scholar 

  215. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacology (Berl) 1973; 32: 327–55

    Google Scholar 

  216. Solyom C, Heseltine GFD, McClure DJ, et al. Behavior therapy vs drug therapy in the treatment of phobic neurosis. Can Psychiatric Assoc J 1973; 18: 25–31

    CAS  Google Scholar 

  217. Solyom C, Solyom L, Lapierre Y, et al. Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 1981; 16: 239–47

    PubMed  CAS  Google Scholar 

  218. Mountjoy CQ, Roth M, Garside RF, et al. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. Br J Psychiatry 1977; 131: 486–92

    PubMed  CAS  Google Scholar 

  219. Liebowitz MR, Fyer AJ, Gorman JM, et al. Phenelzine in social phobia. J Clin Psychopharmacol 1986; 6: 93–8

    PubMed  CAS  Google Scholar 

  220. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279–83

    PubMed  CAS  Google Scholar 

  221. Liebowitz MR, Schneier FR, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992; 49: 290–300

    PubMed  CAS  Google Scholar 

  222. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48: 938–44

    PubMed  CAS  Google Scholar 

  223. Versiani M, Nardi ARE, Mundim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353–60

    PubMed  CAS  Google Scholar 

  224. Van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a reversible MAO-A inhibitor. Eur Neuropsychopharmacol 1992; 2: 21–9

    PubMed  Google Scholar 

  225. Schneier FR. Monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and other antidepressants in pharmacotherapy. In: Stein MB, editor. Social phobia: clinical and research perspectives. Washington, DC: American Psychiatric Press, Inc., 1995: 347–74

    Google Scholar 

  226. Marshall JR. Social phobia: from shyness to stage fright. New York: Basic Books, 1994

    Google Scholar 

  227. Pecknold JC, McClure DJ, Appeltauer L, et al. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br J Psychiatry 1982; 140: 484–90

    PubMed  CAS  Google Scholar 

  228. Schneier FR, Chin SJ, Hollander E, et al. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992; 12: 2–3

    Google Scholar 

  229. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [letter]. J Clin Psychopharmacol 1992; 12: 293–5

    PubMed  CAS  Google Scholar 

  230. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993; 54: 27–32

    PubMed  Google Scholar 

  231. Perugi G, Nassin S, Lenzi M, et al. Treatment of social phobia with fluoxetine. Anxiety 1995; 1: 282–6

    CAS  Google Scholar 

  232. Van Ameringen M, Mancini C, Streiner DL. Sertraline efficacy in social phobia. J Affect Disord 1994; 31: 141–5

    PubMed  Google Scholar 

  233. Van Vliet IM, den Boer JA, Westenberg HGH. Psychopharmacological treatment of social phobia: a double-blind placebocontrolled study with fluvoxamine. Psychopharmacology 1994; 115: 128–34

    PubMed  Google Scholar 

  234. Munjack D. Zoloft (sertraline) in the treatment of social phobia. Neuropsychopharmacology 1994; 10: 196S

    Google Scholar 

  235. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia [letter]. J Clin Psychopharmacol 1995; 15(5): 372–3

    PubMed  CAS  Google Scholar 

  236. Martins EA, Pigott TA, Bernstein SE, et al. Sertraline in the treatment of patients with social phobia. Anxiety 1994; 1: 291–7

    PubMed  Google Scholar 

  237. Katzelnick DJ, Kobak KA, Griest JH, et al. Sertraline for social phobia: a double-blind, placebo controlled crossover study. Am J Psychiatry 1995; 152: 1367–71

    Google Scholar 

  238. Munjack DS, Bruns J, Baltazar PL, et al. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 1990; 5: 151–8

    Google Scholar 

  239. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  240. Schneier FR, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993; 13: 251–6

    PubMed  CAS  Google Scholar 

  241. Clark D, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148: 598–605

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Douglas Hospital, 6875 Boul LaSalle, Verdun, Quebec, QC H3H 1R3, Canada

    John C. Pecknold

Authors
  1. John C. Pecknold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pecknold, J.C. A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders. Drug-Safety 16, 118–132 (1997). https://doi.org/10.2165/00002018-199716020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199716020-00004

Keywords

Search

Navigation